QC
OREX

QCM Cayman’s Orexigen Therapeutics, Inc. OREX Stock Holding History

QCM Cayman’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-1,114
Closed -$69K – 325
2014
Q2 		$69K Buy
+1,114
New +$64.8K 0.03% 223

Other funds holding OREX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

QCM Cayman's OREX Position: Q3 2014 in Review

QCM Cayman sold out of Orexigen Therapeutics, Inc. (OREX) in Q3 2014, closing a stake of 1,114 shares — an estimated $69K sold.

QCM Cayman first reported a position in OREX in Q2 2014 and held it in 1 quarter. The position peaked at $69K in Q2 2014. 128 funds tracked by Wall St. Rank hold OREX as of Q3 2014.

  • QCM Cayman reported no remaining Orexigen Therapeutics, Inc. position as of Q3 2014 after selling out during the quarter.
  • QCM Cayman sold 1,114 Orexigen Therapeutics, Inc. shares in Q3 2014, an estimated $69K.
  • QCM Cayman first reported a position in Orexigen Therapeutics, Inc. in Q2 2014 and held it in 1 quarter.
  • QCM Cayman's Orexigen Therapeutics, Inc. position peaked at $69K in Q2 2014.
  • 128 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q3 2014.

Based on QCM Cayman's 13F filing for Q3 2014, filed 14 Nov 2014.